<DOC>
	<DOCNO>NCT01307423</DOCNO>
	<brief_summary>The purpose study determine whether apremilast safe effective treatment patient psoriatic arthritis previously treat DMARDs . Apremilast propose improve sign symptom psoriatic arthritis ( tender swollen joint , pain , physical function ) treat patient .</brief_summary>
	<brief_title>Efficacy Safety Study Apremilast Treat Active Psoriatic Arthritis ( PsA )</brief_title>
	<detailed_description>Psoriatic arthritis ( PsA ) inflammatory arthritis occur 6-39 % psoriasis patient . The immunopathogenesis PsA , mirror identical see psoriatic plaque , reflect complex interaction among resident dendritic , fibroblastic endothelial cell , inflammatory cell attract synovium cytokine chemokines . Apremilast ( CC-10004 ) novel oral agent modulate multiple inflammatory pathway target phosphodiesterase type 4 ( PDE4 ) enzyme inhibition . Therefore , apremilast potential effective treatment PsA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Male female , age ≥ 18 year time consent . 2 . Must understand voluntarily sign informed consent document prior study related assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . Have document diagnosis Psoriatic Arthritis ( PsA , criterion ) ≥ 3 month duration . 5 . Meet Classification Criteria Psoriatic Arthritis ( CASPAR ) criterion PsA time screen . 6 . Have ≥ 3 swollen AND ≥ 3 tender joint . 7 . Have previously treat diseasemodifying antirheumatic drug ( DMARDS ) ( small molecule biologics ) 8 . Be receive treatment outpatient basis . 9 . If take oral corticosteroid , must stable dose prednisone ≤ 10 mg/day equivalent least 1 month prior screen . 10 . If take nonsteroidal antiinflammatory drug ( NSAIDs ) narcotic analgesic , must stable dose least 2 week prior screen complete Week 24 study visit . 11 . Low potency topical corticosteroid ( Appendix M locally available equivalent ) allow background therapy treatment psoriasis face , axillae groin accordance manufacturer ' suggest usage course study . Subjects scalp psoriasis permit use coal tar shampoo and/or salicylic acid scalp preparation scalp lesion . A nonmedicated skin emollient ( eg , Eucerin cream ) also permit body lesion . Subjects must use treatment within 24 hour prior clinic visit . 12 . Meet follow laboratory criterion : White blood cell count ≥ 3000/mm3 ( ≥ 3.0 x 109/L ) &lt; 14,000/mm3 ( &lt; 14 x 109/L ) Platelet count ≥ 100,000/mm3 ( ≥ 100 x 109/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Aspartate aminotransferase/Serum glutamic oxaloacetic transaminase ( AST/SGOT ) Alanine aminotransferase/Serum glutamic pyruvic transaminase ( ALT/SGPT ) ≤ 2 x upper limit normal ( ULN ) Total bilirubin ≤ 2 mg/dL ( ≤ 34 μmol/L ) Hemoglobin ≥ 9 g/dL ( ≥ 5.6 mmol/L ) Hemoglobin A1c ≤ 9.0 % 13 . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception ( latex condom nonlatex condom NOT make natural [ animal ] membrane [ eg , polyurethane ] ) IP least 28 day last dose IP . 14 . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . FCBP engage activity conception possible must use 2 form contraception investigational product ( IP ) least 28 day last dose IP : one highly effective form ( ie , hormonal , intrauterine device [ IUD ] , tubal ligation , vasectomized partner ) one additional form ( latex condom nonlatex condom NOT make natural [ animal ] membrane [ eg , polyurethane ] , diaphragm , sponge ) . If one highly effective form contraception use , 2 form barrier contraception must use , ie , latex condom nonlatex condom NOT make natural ( animal ) membrane ( eg , polyurethane ) either follow : sponge spermicide diaphragm spermicide . 1 . History clinically significant ( determined Investigator ) cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic disease , major uncontrolled disease . 2 . Any condition , include presence laboratory abnormality place subject unacceptable risk he/she participate study confounds ability interpret data study . 3 . Clinically significant abnormality 12lead electrocardiography ( ECG ) Screening . 4 . Pregnant breast feeding . 5 . History allergy component IP . 6 . Hepatitis B surface antigen positive screening . 7 . Hepatitis C antibody positive screening . 8 . AST/SGOT and/or ALT/SGPT &gt; 1.5 x ULN total bilirubin &gt; ULN albumin &lt; low limit normal ( LLN ) . 9 . History positive Human Immunodeficiency Virus ( HIV ) , congenital acquire immunodeficiency ( eg , Common Variable Immunodeficiency Disease ) . 10 . Active tuberculosis history incompletely treated tuberculosis . 11 . Clinically significant abnormality base upon chest radiograph least PA view ( radiograph must take within 12 week prior Screening Screening visit ) . An additional lateral view strongly recommend require . 12 . Active substance abuse history substance abuse within 6 month prior Screening . 13 . Bacterial infection require treatment oral injectable antibiotic , significant viral fungal infection , within 4 week Screening . Any treatment infection must complete least 4 week prior Screening . 14 . Malignancy history malignancy ( except treat [ ie , cure ] basal cell squamous cell situ skin carcinoma treat [ ie , cure ] cervical intraepithelial neoplasia [ CIN ] carcinoma situ cervix ) . 15 . Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization . 16 . Erythrodermic , guttate , pustular psoriasis . 17 . Topical therapy psoriasis , except note Inclusion Criteria , within 2 week randomization ( include limited topical corticosteroid , topical retinoids vitamin D analog preparation , tacrolimus , pimecrolimus , anthralin ) . 18 . Rheumatic autoimmune disease PsA , include systemic lupus erythematosis ( SLE ) , mixed connective tissue disease ( MCTD ) , scleroderma , polymyositis . 19 . Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis ( Appendix Q ) . 20 . Prior history current inflammatory joint disease PsA ( eg , gout , reactive arthritis , RA , ankylose spondylitis , Lyme disease ) . 21 . Prior use disease modify antirheumatic drug ( DMARDS ; small molecule biologics ) . 22 . Use follow systemic therapy ( y ) within 4 week randomization , include limited corticosteroid ( except note inclusion criterion ) , oral retinoids fumaric acid ester . 23 . Use phototherapy within 4 week randomization ( ie , UVB , PUVA ) . 24 . Previous treatment cell deplete therapy , include investigational agent ( eg , rituximab , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 , antiCD20 ) . 25 . Treatment intravenous gamma globulin , plasmapheresis , Prosorba® column within 6 month baseline . 26 . Any previous treatment alkylating agent cyclophosphamide chlorambucil , total lymphoid irradiation . 27 . Prior treatment apremilast . 28 . Use investigational drug within 4 week randomization , 5 pharmacokinetic/ pharmacodynamic half life , know ( whichever longer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>inflammation</keyword>
	<keyword>skin condition</keyword>
	<keyword>inflammatory cell</keyword>
	<keyword>apremilast</keyword>
	<keyword>CC-10004</keyword>
	<keyword>phosphodiesterase type 4</keyword>
</DOC>